In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."
More from Investing
When we combine the poorly placed HOOD IPO with the startling miss and guidance markdown in Amazon, the stage seems to be set for a correction.
Good money management is such a powerful tool that traders should be able to make money even when stock selection is entirely random.
There were positive earnings call takeaways for AWS, YouTube and Microsoft Dynamics, among other businesses.
The Russell 2000 climbed this week as the big-cap tech names reported and Robinhood's initial public offering disappointed. Now will we see a deeper correction?